At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 175 enrolled
Drug / intervention
Bulevirtide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta
In Brief
A Phase 2 clinical trial evaluating Bulevirtide and Peginterferon Alfa-2a (PEG-IFN alfa) for Chronic Hepatitis Delta. Completed, enrolled 175 participants across 20 sites in 4 countries.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis Delta
CountriesFrance, Moldova, Romania, Russia
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMay 2019
Primary CompletionApr 2022
Study CompletionSep 2022
TodayJul 2026
First PostedFeb 25, 2019
Enrollment StartMay 31, 2019
Primary CompletionApr 5, 2022
Study CompletionSep 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.4 years ago
Interventions
Bulevirtidedrug
Administered via subcutaneous injections
Peginterferon Alfa-2a (PEG-IFN alfa)drug
Administered via subcutaneous injections